Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients
Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients
This study will evaluate the safety and tolerability of the cfor the first time in mild to
 moderate COPD patients.
Inclusion Criteria:

 -  Male adults or female adults of non-childbearing potential who are between 40 and 75
 years of age (inclusive).

 -  Subjects with a clinical diagnosis of COPD in accordance with the European Respiratory
 Society Consensus Statement and subjects categorised with moderate COPD as defined by
 the GOLD guidelines of 2006 [GOLD, 2006]

 -  Subjects with a cigarette smoking history of ≥ 10 pack years (1 pack year = 20
 cigarettes smoked per day for 1 year or the equivalent). Both current and former
 smokers are eligible to be enrolled. A former smoker is defined as a subject who has
 not smoked for ≥6 months at Visit 1.

 -  Subjects with a post-bronchodilator FEV1 to FVC ratio (FEV1/FVC) < 0.7 at Visit 1.
 Subjects will be assessed 30 (± 5) minutes after receiving salbutamol 400 μg.

 -  Subjects with a post-bronchodilator FEV1 ≥ 50% and < 80% of predicted normal for
 height, age and sex at Visit 1. Subjects will be assessed 30 (± 5) minutes after
 receiving salbutamol 400 μg.

 -  Subjects with a normal echocardiogram at screening, as defined by the absence of
 clinically significant wall motion, chamber size or valvular abnormalities

 -  The subject must be capable of giving informed consent and can comply with the study
 requirements and timetable.

 Exclusion Criteria:

 -  Women who are pre-menopausal and of child-bearing potential.

 -  Subjects weighing less than 50 kilograms (kg).

 -  Subjects who are obese defined as having a body mass index (BMI) > 30.

 -  Subjects with a current diagnosis of asthma.

 -  Subjects who have required hospitalisation or treatment with oral corticosteroids
 and/or antibiotic therapy for acute worsening of COPD or lower respiratory tract
 infection in the 6 weeks prior to Screening.

 -  Subjects who have received treatment with oral, intravenous, topical or
 intra-articular corticosteroids within 6 weeks of Screening or thereafter

 -  Subjects with active tuberculosis, sarcoidosis or clinically overt bronchiectasis.

 -  Subjects with a history of any type of malignancy with the exception of successfully
 treated squamous cell cancer of the skin.

 -  Subjects with rheumatoid arthritis, connective tissue disorders and other conditions
 known to be associated with chronic inflammation (e.g. Inflammatory Bowel Disease).

 -  Subjects with chronic infections (lasting longer than 6 months) such as gingivitis,
 periodontitis, prostatitis, gastritis, and urinary tract infections.

 -  Subjects with any acute infection, sinus symptoms, or significant trauma (burns,
 fractures).

 -  Subjects with clinically significant renal disease, diabetes mellitus/metabolic
 syndrome, hypertension or any other clinically significant cardiovascular,
 neurological, endocrine, or haematological abnormalities that are uncontrolled on
 permitted therapy.

 -  Subjects who have participated in any GSK study/studies involving administration of
 COA.

 -  The subject has a screening ECG parameters outside of ranges specified in protocol.

 -  Subjects with hypoxaemia

 -  Risk factors for human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C
 infection at Screening (Visit 1).

 -  Subjects who have undergone surgery including lung volume reduction surgery in the
 last six months or have conditions that prevent them from performing spirometry.

 -  Subjects with a history (or suspected history) of alcohol misuse or any other
 recreational substance abuse.

 -  Subjects who require treatment with any of the following from the start of the run-in
 period (Day -14) until the end of the treatment phase:

 -  Inhaled corticosteroids

 -  Inhaled cromolyn sodium or nedocromil

 -  Xanthines (theophylline preparations).

 -  Leukotriene modifiers

 -  Tiotropium

 -  Long-acting inhaled beta2-agonists (salmeterol, formoterol)

 -  Oral beta2-agonists

 -  Subjects who are unable to abstain from other courses of medication during the run in
 phase including non-steroidal anti-inflammatory drugs (NSAIDs), anti-depressant drugs,
 anti-histamines, anti-rhinitis or hay fever medication, other than short acting
 inhaled beta-agonists, ipratropium bromide and paracetamol (up to 4 g per day) for the
 treatment of minor ailments (eg headache) from 48h before the first dose until the
 follow-up visit. Subjects requiring medication between dosing and follow up may be
 excluded at the principal investigators discretion.

 -  Subjects with any known hypersensitivity to salbutamol or ipratropium bromide.

 -  Subjects who are participating or plan to participate in the active phase of a
 pulmonary rehabilitation programme during the study.

 -  Subjects who have received an investigational drug within 30 days or within five drug
 half-lives of the investigational drug (whichever is longer).

 -  Subjects with any clinically relevant abnormality detected by the assessments at
 Screening.

 -  Subjects who have experienced an exacerbation during the run-in period requiring
 treatment with oral corticosteroids and/or macrolide antibiotics and/or
 hospitalisation.